REG - GENinCode PLC - Result of AGM

GenincodeAnnouncement

27/06/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa2206Ua&default-theme=true

RNS Number : 2206U  GENinCode PLC  27 June 2024

GENinCode Plc

("GENinCode" or the "Company")

 

Result of AGM

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease and ovarian cancer, announces that
at the Annual General Meeting held earlier today, all resolutions were duly
passed.

 

A copy of the voting results can be found on the website later today here
(https://investors.genincode.com/investors) .

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 GENinCode Plc                       www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Cavendish Capital Markets Limited   Tel: +44 (0)20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks / Harriet Ward (Corporate Broking)
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                   Tel: 020 7933 8780 or genincode@walbrookpr.com

                                                                     (mailto:genincode@walbrookpr.com)
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

 

About GENinCode:

 

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease and ovarian cancer. Cardiovascular disease is the
leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventive care and treatment strategies. GENinCode invitro-diagnostic
molecular tests combine clinical algorithms and AI bioinformatics to advance
patient risk assessment to prevent the onset of cardiovascular disease and
ovarian cancer.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBSGDLRUDDGSR